Adenosine Triphosphate (ATP) News and Research

RSS

Researchers discover HIV-1 resists AZT drug

Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS. The scientists, who report their findings in Nature Structural & Molecular Biology, believe their discovery helps researchers understand how important anti-AIDS treatments can fail and could help AIDS researchers develop more effective treatment for the disease.

20 Sep 2010

Mechanism linking brain activity to sleep discovered

Washington State University researchers have discovered the mechanism by which the brain switches from a wakeful to a sleeping state. The finding clears the way for a suite of discoveries, from sleeping aids to treatments for stroke and other brain injuries.

15 Sep 2010

New gene required for memory formation identified

A team led by a Scripps Research Institute scientist has for the first time identified a new gene that is required for memory formation in Drosophila, the common fruit fly. The gene may have similar functions in humans, shedding light on neurological disorders such as Alzheimer's disease or human learning disabilities.

9 Sep 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

Discovery of Hsp90 protein's pattern of motion paves way for new drug target in cancer therapy

The protein Hsp90 plays a significant role in the survival of cells that are exposed to stress. Researchers at the Technische Universitaet Muenchen (TUM) uncovered this protein's mode of operation some time ago - but now Hsp90 has surprised even the experts with an unexpected pattern of motion. The results are published in the current online issue of the renowned science journal PNAS and may help researchers discover specific cancer medication.

24 Aug 2010

Scientists identify role of PNPASE in regulating RNA import into mitochondria

Researchers at UCLA's Jonsson Comprehensive Cancer Center and the departments of Chemistry and Biochemistry and Pathology and Laboratory Medicine have uncovered a role for an essential cell protein in shuttling RNA into the mitochondria, the energy-producing "power plant" of the cell. The import of nucleus-encoded small RNAs into mitochondria is essential for the replication, transcription and translation of the mitochondrial genome, but the mechanisms that deliver RNA into mitochondria remain poorly understood.

7 Aug 2010

HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.

29 Jul 2010

Calcium transfer impacts fuel mechanism for normal cell metabolism

University of Pennsylvania School of Medicine researchers have described a previously unknown biological mechanism in cells that prevents them from cannibalizing themselves for fuel. The mechanism involves the fuel used by cells under normal conditions and relies on an ongoing transfer of calcium between two cell components via an ion channel. Without this transfer, cells start consuming themselves as a way of to get enough energy.

28 Jul 2010

Neogen fiscal 2010 net income increases 26% to $17.5M

Neogen Corporation announced today that its net income for its 2010 fiscal year, which ended May 31, increased 26% from the previous year to $17,521,000. Net income in the fiscal year increased to $0.76 per share, compared to the prior year's $0.61, adjusted for a 3-for-2 stock split that was effective Dec. 15, 2009.

20 Jul 2010

New technique to measure ATP from arterioles helps understand hypertension in women

Research at the University of Arkansas took a step toward understanding hypertension in women by using a new technique to examine the release of a neurotransmitter in small blood vessels.

20 Jul 2010

AdVnt launches 15 Minute Black Mold Detection Test

AdVnt Biotechnologies, the company known for producing BioWarfare Agent Detection Devices for HAZMAT First Response Teams around the globe to help them rapidly detect such biological agents as Anthrax, Ricin and Botulinum, has just released its newest product for In-Home and Professional use. Building on the expertise gained in the international arena of BioWarfare Agent Detection, AdVnt is now applying its R&D expertise to help defend against another type of bio threat that could be growing in the walls and under the floorboards in your own home.

30 Jun 2010

Pluristem advances toward PLX-PAD Phase IIb clinical trials for CLI and Moderate-severe Claudication

Pluristem Therapeutics Inc. today announced that following its meeting with the Paul Ehrlich Institute (PEI), the German regulatory authority for advanced therapy products (ATP), the company is advancing toward designing two Phase IIb clinical trials for its placenta-derived cell therapy product, PLX-PAD, for the treatment of Critical Limb Ischemia (CLI) and Moderate-severe Claudication.

29 Jun 2010

ATP-driven bioluminescence predicts children at high risk for tooth decay: OHSU study

Researchers at the Oregon Health & Science University School of Dentistry have determined that ATP-driven (adenosine triphosphate-driven) bioluminescence - a way of measuring visible light generated from ATP contained in bacteria - is an innovative tool for rapidly assessing in children at the chair-side the number of oral bacteria and amount of plaque that can ultimately lead to tooth decay.

23 Jun 2010

Vitro, HemoGenix launch new stem cell testing products at International Society for Stem Cell Research meeting

Vitro Diagnostics, Inc., dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world.

16 Jun 2010

New breakthrough may help understand human obesity and eating disorders

A nutrient that's common to all living things can make hibernating marmots hungry - a breakthrough that could help scientists understand human obesity and eating disorders, according to a new study by a Colorado State University biologist.

3 Jun 2010

Corvalen M introduced for treatment of fibromyalgia symptoms

Fibromyalgia affects as many as one in 50 Americans, 90 percent of whom are women. Yet, despite its nearly epidemic status, patients still often rely on pharmaceutical options solely for treatment. That's why Bioenergy Life Science, Inc. has introduced Corvalen M, a natural treatment option for fibromyalgia symptoms.

28 May 2010

Highlights from June 2010 issue of American Journal of Pathology

Dr. Kanneboyina Nagaraju and colleagues at the Children's National Medical Center, Washington, DC demonstrate that affected muscle may directly contribute to inflammation in muscular dystrophy. Their report can be found in the June 2010 issue of The American Journal of Pathology.

26 May 2010

New data from MVP trial on ICDs shows health care use burden

Medtronic, Inc. today released new data from the MVP trial that implantable defibrillator patients receiving anti-tachycardia pacing were less likely to have health care utilization after treatment as compared to those receiving shock therapy.

17 May 2010

Poster on dual Erk/PI3K inhibitors presented at AACR 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today presented a poster on dual Erk/PI3K inhibitors and made an oral presentation on its selective Erk inhibitors, at the American Association for Cancer Research Annual Meeting in Washington, D.C.

21 Apr 2010

Medtronic's Advisa DR MRI SureScan pacemaker commercially available in selected European geographies

Medtronic, Inc. announced today the commercial availability of the Advisa DR MRI™ SureScan™ pacemaker in selected European geographies. The Advisa DR MRI SureScan pacemaker is the company’s second-generation pacemaker in a portfolio of devices from Medtronic designed, tested, and approved for use as labeled with MRI machines in selected European geographies.

18 Mar 2010